medwireNews: Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.
Addressing attendees at the 15th ATTD conference in Barcelona, Spain, Marina Francesca Strati (Giannina Gaslini Pediatric Research Institute, Genoa) reported that, during the first month after initiation, the 51 MiniMed 780G users in the study had significantly larger improvements in time in range than the 39 Control IQ users, at an average of 19.1% versus 9.8%.
They also had a significantly larger reduction in average glucose levels, by an average of 31.0 versus 7.1 mg/dL (1.72 vs 0.39 mmol/L).
However, Strati stressed that the Control IQ users had better baseline glucose control than the MiniMed 780G, with average glycated hemoglobin levels of 7.1% versus 7.8% (54 vs 62 mmol/mol).
The MiniMed 780G users therefore had “more room for improvement in the 1 month of therapy,” said the presenter.
The treatment difference after accounting for baseline differences between the groups was 9.3% in favor of the MiniMed 780G for time in range and 23.9 mg/dL (1.32 mmol/L) for average glucose levels.
This larger reduction in glucose levels with the MiniMed 780G came at the expense of a slight increase in time below range (<70 mg/dL, 3.9 mmol/L), at an average of 0.37%, whereas time below range reduced in the Control IQ users by an average of 0.68%, creating a significant difference between the two systems for this outcome.
Control IQ users also had a significantly larger reduction in glucose variability than the MiniMed 780G users did, at an average reduction in the coefficient of variability of 5.68% versus 0.32%.
In addition to having better baseline glycemic control, the Control IQ system users were significantly younger than those using the MiniMed 780G, at an average of 16.0 versus 24.4 years, were significantly younger at the time of diabetes onset, at an average of 7.8 versus 11.2 years, and had a shorter diabetes duration, at 8.2 versus 13.2 years.
“We believe that understanding the strengths and the limitations of [advanced hybrid closed-loop] devices will help us tailor pump therapy and then choose the right device depending on the patient that we have before us,” Strati concluded.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group